Chlamydia and gonorrhea testing rates remain critically low across the United States, according to a sweeping analysis of 2023 health insurance claims covering 2 million individuals. The data indicates suboptimal screening for the two most prevalent bacterial sexually transmitted infections, chlamydia trachomatis and neisseria gonorrhoeae.
Among the high-risk cohort aged 16 to 24, only 23.7% of females and 6.9% of males were tested. The analysis revealed a stark missed opportunity in routine care; testing rates jumped to 56% for young women who had at least one outpatient obstetrics and gynecology visit.
A clear age gradient showed testing rates declining further in older groups for both sexes. Geographic location also heavily influenced whether a patient was screened, with a median odds ratio of 1.34 for females aged 16-24. This means similar individuals could be 34% more likely to receive testing simply by living in a different state.
Diagnostic approaches remain non-standardized. For symptomatic females tested for chlamydia or gonorrhea, providers frequently co-ordered additional panels, including Trichomonas vaginalis in 62% of cases. The findings point to an urgent need for standardized screening pathways to fix persistent detection gaps in at-risk populations.